共 44 个 OTC 专论产品
| 序号 | NDC编码 | 商品名 | 剂型 | 上市日期 | 专论编号 |
|---|---|---|---|---|---|
| 1 | 69256-128-22 | Extra Strength Antacid | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 2 | 69256-129-22 | Extra Strength Antacid Tropical Fruit | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 3 | 69256-130-22 | Extra Strength Antacid | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 4 | 69256-127-22 | Extra Strength Assorted Fruit Antacid | TABLET, CHEWABLE | 2025-02-06 | M001 |
| 5 | 69256-113-17 | Regular Strength Antacid Peppermint | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 6 | 69256-183-23 | Extra Strength Smooth Antacid | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 7 | 69256-517-05 | Maximum Strength Antacid | LIQUID | 2025-02-06 | M001 |
| 8 | 69256-508-40 | Maximum Strength Antacid Cherry | LIQUID | 2025-02-06 | M001 |
| 9 | 69256-178-68 | Ultra Strength Antacid Assorted Fruit | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 10 | 69256-138-17 | Regular Strength Antacid | TABLET, CHEWABLE | 2025-02-07 | M001 |
| 11 | 69256-171-68 | Ultra Strength Assorted Berry Antacid | TABLET, CHEWABLE | 2024-02-04 | M001 |
| 12 | 69256-134-73 | Extra Strength Gas Relief Cherry | TABLET, CHEWABLE | 2025-01-29 | M002 |
| 13 | 69256-503-05 | Regular Strength Antacid Antigas | LIQUID | 2025-02-06 | M002 |
| 14 | 69256-520-09 | Infants Gas relief | SOLUTION/ DROPS | 2025-02-05 | M002 |
| 15 | 69256-135-73 | Extra Strength Gas Relief | TABLET, CHEWABLE | 2025-02-05 | M002 |
| 16 | 69256-037-03 | Benzethonium chloride Plus Dyclonine hydrochloride | LIQUID | 2014-07-10 | M003 |
| 17 | 69256-213-91 | Harris Teeter Iodine Tincture Mild | LIQUID | 1979-01-01 | M003 |
| 18 | 69256-275-16 | Rubbing Alcohol 70 Percent Isopropyl | LIQUID | 2014-10-31 | M003 |
| 19 | 69256-277-16 | Isopropyl alcohol 91 percent | LIQUID | 2017-02-28 | M003 |
| 20 | 69256-970-60 | Harris Teeter | SWAB | 2021-01-01 | M003 |
| 21 | 69256-034-53 | Tolnaftate | AEROSOL, SPRAY | 2017-12-21 | M005 |
| 22 | 69256-038-46 | Miconazole Nitrate | AEROSOL, SPRAY | 2017-12-21 | M005 |
| 23 | 69256-039-46 | Miconazole Nitrate | AEROSOL, POWDER | 2017-05-22 | M005 |
| 24 | 69256-311-10 | Magnesium Citrate | LIQUID | 2024-02-06 | M007 |
| 25 | 69256-395-01 | Epsom Salt | GRANULE | 2018-01-31 | M007 |
| 26 | 69256-515-96 | Harris Teeter Castor Oil | LIQUID | 2008-01-01 | M007 |
| 27 | 69256-527-04 | Stomach Relief | LIQUID | 2025-02-06 | M008 |
| 28 | 69256-528-04 | Max Strength Stomach Relief | LIQUID | 2025-02-06 | M008 |
| 29 | 69256-860-32 | Sleep Aid Maximum Strength | CAPSULE | 2020-01-31 | M010 |
| 30 | 69256-916-32 | Nighttime Sleep Aid Maximum Strength | CAPSULE | 2020-01-31 | M010 |
| 31 | 69256-337-06 | Mucus Relief Severe Congestion and Cough Maximum Strength | LIQUID | 2021-05-28 | M012 |
| 32 | 69256-343-12 | Nighttime Cold and Flu | LIQUID | 2021-04-30 | M012 |
| 33 | 69256-344-12 | Night Time Cold and Flu original | LIQUID | 2021-04-30 | M012 |
| 34 | 69256-385-08 | Tussin Cough and Chest Congestion DM adult | LIQUID | 2021-04-30 | M012 |
| 35 | 69256-505-06 | Mucus Relief DM Max Maximum Strength | LIQUID | 2021-05-28 | M012 |
| 36 | 69256-466-12 | Daytime Cold and Flu Non drowsy | LIQUID | 2021-04-30 | M012 |
| 37 | 69256-467-24 | Daytime Nighttime Cold and Flu | KIT | 2021-05-28 | M012 |
| 38 | 69256-058-01 | Harris Teeter Eye Drops Maximum Redness Relief | SOLUTION | 2023-03-24 | M018 |
| 39 | 69256-662-01 | Harris Teeter Eye Drops Advanced Relief | SOLUTION/ DROPS | 2023-03-19 | M018 |
| 40 | 69256-268-16 | Hydrogen Peroxide 3 Percent | LIQUID | 2014-10-31 | M022 |
| 41 | 69256-035-09 | Salicylic Acid | LIQUID | 2017-12-21 | M028 |
| 42 | 69256-030-09 | Salicylic Acid | PATCH | 2017-12-20 | M030 |
| 43 | 69256-036-09 | Salicylic Acid | LIQUID | 2017-12-21 | M030 |
| 44 | 69256-031-04 | Salicylic Acid | PATCH | 2012-01-03 | M030 |
标准化流程确保专论判定准确、文件齐备、标签合规,缩短整体办理周期。
提交配方表、活性成分、宣称用途及现有检测报告,进行初步合规评估。
比对21 CFR对应专论条款,确认产品归属类别及GRASE活性成分浓度范围。
指定美国代理人,完成FDA药品生产设施注册与产品列名申请。
按21 CFR 201.66制作Drug Facts标签,核对警示语、适应症与使用方法。
提供完整合规文件包,协助清关申报与上市后持续合规维护。
关于 OTC 化妆品出口美国合规的常见疑问解答。
微信号:KOL123567
添加时请备注「公司-职务-姓名」
优先安排资深法规专家 1 对 1 对接
我们已收到您的合规咨询需求
资深 FDA 法规顾问将在 1 个工作日内与您联系